LKPC's subsidiary has obtained the drug registration certificate for Vardenafil Hydrochloride Tablets
LKPC's subsidiary, Saiter, recently obtained the drug registration certificate for Vardenafil Hydrochloride Tablets issued by the National Medical Products Administration. This drug is a new registration classified as Category 4 generic drug, which has passed the consistency evaluation of quality and efficacy for generic drugs, and is suitable for the treatment of male erectile dysfunction
According to the Zhitong Finance APP, LKPC (600789.SH) announced that its holding subsidiary, Shandong LKPC Group Saiter Co., Ltd. (hereinafter referred to as "Saiter Company"), has received the "Drug Registration Certificate" (Approval No.: 2025S02296) issued by the National Medical Products Administration for the drug hydrochloride vardenafil tablets (hereinafter referred to as "the drug"). This drug is approved as a generic drug under the new registration classification category 4 and is considered to have passed the consistency evaluation of quality and efficacy for generic drugs.
Hydrochloride vardenafil tablets are a phosphodiesterase inhibitor drug. Vardenafil increases the release of endogenous nitric oxide in the corpus cavernosum under sexual stimulation by inhibiting phosphodiesterase type 5 (PDE5), which degrades cyclic guanosine monophosphate (cGMP) in the human penile corpus cavernosum, leading to smooth muscle relaxation and increased blood flow in the human penile corpus cavernosum, thereby enhancing the natural response to sexual stimulation. This product is suitable for the treatment of erectile dysfunction in men
